Our CEO, Dr James Garner sat down with Karen Tan from Proactive Investors in Sydney to discuss the presentation of new data from the company’s Cantrixil trial in ovarian cancer at the American Association of Cancer Research (AACR) 2019 Annual Meeting on April 1.
The interview covers:
- The huge need for new treatments for ovarian cancer
- The importance of being selected to present at the AACR 2019 Annual Meeting
- An overview of the positive new data from Part A of the phase I study of Cantrixil
- The expected timeframe for the conclusion of the phase I study of Cantrixil
